New York, NY, and Tel Aviv, ISRAEL, Sept. 09, 2022 (GLOBE NEWSWIRE) — through NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a complete medical diagnostics and associated options firm, at present launched the Nasdaq MarketSite interview between Moneta Advisory Group’s Managing Partner Marc LoPresti and CEO Gerald Commissiong, discussing the affect of Long COVID on the economy and the way SARS-CoV-2 viral persistence is damaging population-level immunity resulting in the rise of viral outbreaks equivalent to MonkeyPox. A hyperlink to the interview might be discovered at: https://youtu.be/55pv1zKCDgI.
Todos Medical, by means of its majority owned subsidiary 3CL Pharma, has commercialized Tollovid™, the 3CL protease inhibitor immune help dietary complement with latest information in acute and Long COVID, with a medical proof of idea examine deliberate in Long COVID. 3CL can also be creating the drug candidate Tollovir™, a mixture 3CL protease inhibitor and CCR5 antagonist twin mechanism therapeutic at the moment making ready to enroll a brand new 46-patient remedy arm following a profitable Phase 2a medical trial in hospitalized (extreme/essential) COVID-19 sufferers and confirmatory biomarker information. Additionally, the Company has introduced forth TolloTest™, a diagnostic assay measuring 3CL protease exercise which correlates with SARS-CoV-2 replication as measured by PCR ct worth, that has efficiently accomplished medical proof of idea research in hospitalized and outpatient settings. The Company believes TolloTest holds important worth in measuring viral exercise in Long COVID.
Harvard economist David Cutler lately revised the estimated value of Long COVID to the US economy to be $3.7 trillion. Dr. Cutler notes on his web site: “Data suggest that 22-38% of people with COVID will have at least one symptom 12 weeks after initial onset, and 12-17% will have three or more symptoms. With 80.5 million confirmed COVID cases in the United States, this implies at least 9.6 million people with three or more symptoms of long COVID. The most common symptom of long COVID is fatigue, but every organ system has been implicated.”
To be taught extra in regards to the 3CL protease in SARS-CoV-2 replication, please go to www.3clpro.com. To buy Tollovid please go to Amazon or www.MyTollovid.com.
About Todos Medical Ltd.
Founded in Rehovot, Israel with places of work in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic options for the early detection of a wide range of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening expertise utilizing peripheral blood evaluation that examines most cancers’s affect on the immune system, on the lookout for biochemical adjustments in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening assessments, TMB-1 and TMB-2 have obtained a CE mark in Europe. Todos lately acquired U.S.-based medical diagnostics firm Provista Diagnostics, Inc. to achieve rights to its Alpharetta, Georgia-based CLIA/CAP licensed lab at the moment performing PCR COVID testing, Long COVID Panel analyses, and Provista’s proprietary commercial-stage Videssa® breast most cancers blood take a look at. More info on Provista is out there at www.provistadx.com.
Todos can also be creating blood assessments for the early detection of neurodegenerative issues, equivalent to Alzheimer’s illness. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood take a look at that determines the power of peripheral blood lymphocytes (PBLs) and monocytes to face up to an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that sure ailments, most notably Alzheimer’s illness, are the results of compromised mobile equipment that results in aberrant cell cycle re-entry by neurons, which then results in apoptosis. LymPro is exclusive in using peripheral blood lymphocytes as a surrogate for neuronal cell perform, suggesting a standard relationship between PBLs and neurons within the mind.
Todos fashioned the Israeli-based majority-owned three way partnership 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all the mental property surrounding 3CL protease–primarily based diagnostic testing and growth of 3CL protease botanical and pharmaceutical inhibitors that concentrate on a elementary reproductive mechanism of coronaviruses. 3CL Pharma, by means of Todos’ model, has commercialized the 3CL protease inhibitor immune help dietary complement Tollovid™ within the United States, is creating the twin mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir™, whereas additionally creating the 3CL protease diagnostic TolloTest™.
To buy Tollovid please go to Amazon or www.MyTollovid.com. For extra info, please go to https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained on this press launch might represent forward-looking statements. For instance, forward-looking statements are used when discussing our anticipated medical growth applications and medical trials. These forward-looking statements are primarily based solely on present expectations of administration, and are topic to important dangers and uncertainties that would trigger precise outcomes to vary materially from these described within the forward-looking statements, together with the dangers and uncertainties associated to the progress, timing, value, and outcomes of medical trials and product growth applications; difficulties or delays in acquiring regulatory approval or patent safety for product candidates; competitors from different biotechnology corporations; and our skill to acquire extra funding required to conduct our analysis, growth and commercialization actions. In addition, the next components, amongst others, may trigger precise outcomes to vary materially from these described within the forward-looking statements: adjustments in expertise and market necessities; delays or obstacles in launching our medical trials; adjustments in laws; incapacity to well timed develop and introduce new applied sciences, merchandise and purposes; lack of validation of our expertise as we progress additional and lack of acceptance of our strategies by the scientific group; incapacity to retain or appeal to key workers whose data is crucial to the event of our merchandise; unexpected scientific difficulties which will develop with our course of; larger value of ultimate product than anticipated; lack of market share and stress on pricing ensuing from the competitors; and laboratory outcomes that don’t translate to equally good leads to actual settings, all of which may trigger the precise outcomes or efficiency to vary materially from these contemplated in such forward-looking statements. Except as in any other case required by regulation, Todos Medical doesn’t undertake any obligation to publicly launch any revisions to those forward-looking statements to replicate occasions or circumstances after the date hereof or to replicate the prevalence of unanticipated occasions. For a extra detailed description of the dangers and uncertainties affecting Todos Medical, please consult with its stories filed now and again with the U.S. Securities and Exchange Commission.
Todos Corporate Contact:
Daniel Hirsch CFO
Todos Medical
917-983-4229 x 104
[email protected]
Todos Press Contact:
Kyle Kappmeier
JConnelly
Vice President
973-975-7827
[email protected]
